SCHEMBL5511378

SCHEMBL5511378

CS[SiH2]Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9566523 0.59
SCHEMBL14438144 0.59
Methylsulfanylmethane SCHEMBL14352912 0.54
SCHEMBL9328851 0.54
Ethane SCHEMBL2058527 0.54
SCHEMBL159813 0.54
SCHEMBL22226 0.54
Methylsulfanylmethane SCHEMBL3444503 0.50
Methyl Alcohol SCHEMBL9067144 0.50
Methylsulfanylmethane SCHEMBL29540305 0.50

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253183-B2 Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-07 US disclosed
US-7115624-B1 Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48 NOVO NORDISK A/S (DK) 2006-10-03 US disclosed
EP-1162201-B1 Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives JANSSEN PHARMACEUTICA NV (BE) 2006-03-29 EP disclosed
US-7019026-B1 Modulators of Protein Tyrosine Phosphatases (PTPases) NOVO NORDISK A/S (DK) 2006-03-28 US disclosed
EP-1214325-B1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) NOVO NORDISK AS (DK) 2005-11-09 EP disclosed
US-20040198771-A1 Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation END DAVID WILLIAM (US) 2004-10-07 US disclosed
US-6743805-B2 TREATING VASCULAR PROLIFERATIVE DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2004-06-01 US disclosed
US-6734194-B2 TO PREVENT OR TREAT VASCULAR PROLIFERATIVE DISORDERS SUCH AS ATHEROSCLEROSIS AND RESTENOSIS JANSSEN PHARMACEUTICA N.V. (BE) 2004-05-11 US disclosed
US-20030229118-A1 Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation END DAVID WILLIAM (US) 2003-12-11 US disclosed
EP-0988038-B1 (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION JANSSEN PHARMACEUTICA NV (BE) 2002-08-14 EP disclosed
EP-1162201-A2 Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2001-12-12 EP disclosed
US-6294521-B1 SUGAR PHOSPHATES AUSTRALIAN NATIONAL UNIVERSITY (AU) 2001-09-25 US disclosed
WO-2001019831-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) NOVO NORDISK A/S (DK) 2001-03-22 WO disclosed
WO-2001017516-A2 METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 NOVO NORDISK A/S (DK) 2001-03-15 WO disclosed
US-6169096-B1 FOR INHIBITING TUMOR GROWTH IN A MAMMAL JANSSEN PHARMACAEUTIC N.V. (BE) 2001-01-02 US disclosed
EP-0988038-A1 (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-29 EP disclosed
US-6037350-A USEFUL AS ANTICANCER AGENTS FOR TUMORS JANSSEN PHARMACEUTICA, N.V. (BE) 2000-03-14 US disclosed
WO-1998055124-A1 (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION JANSSEN PHARMACEUTICA N.V. (BE) 1998-12-10 WO disclosed
EP-0865440-A1 FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1998-09-23 EP disclosed
WO-1997021701-A1 FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1997-06-19 WO disclosed